Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2015-06-26
- Lead Sponsor
- Prof Jamie Cavenagh
- Target Recruit Count
- 54
- Registration Number
- NCT02145715
- Locations
- ๐ฌ๐ง
Birmingham Heartlands Hospital, Birmingham, UK, United Kingdom
๐ฌ๐งSt Bartholomew's Hospital, London, United Kingdom
๐ฌ๐งUniversity College London Hospitals NHS Foundation Trust, London, United Kingdom
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Jason Valent
- Target Recruit Count
- 16
- Registration Number
- NCT02057640
- Locations
- ๐บ๐ธ
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
๐บ๐ธCleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2023-01-20
- Target Recruit Count
- 17
- Registration Number
- NCT02032810
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT01965353
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธDuke University Medical Center, Durham, North Carolina, United States
Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-06-24
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Armando Santoro, MD
- Target Recruit Count
- 24
- Registration Number
- NCT01884428
- Locations
- ๐ฎ๐น
Istituto Clinico Humanitas, Rozzano, MI, Italy
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator
- First Posted Date
- 2013-03-04
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01802879
- Locations
- ๐บ๐ธ
Georgia Regents University SC-2, Augusta, Georgia, United States
๐บ๐ธCity of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1), Duarte, California, United States
๐บ๐ธDana Farber Cancer Institute Reg. Ped, Boston, Massachusetts, United States
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)
- First Posted Date
- 2012-09-26
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- John Mascarenhas
- Target Recruit Count
- 15
- Registration Number
- NCT01693601
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 15
- Registration Number
- NCT01680094
- Locations
- ๐ฉ๐ฐ
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark
Panobinostat Biological Correlates Study
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 30
- Registration Number
- NCT01658241
- Locations
- ๐ฆ๐บ
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Ajai Chari
- Target Recruit Count
- 32
- Registration Number
- NCT01651039
- Locations
- ๐บ๐ธ
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.